摘要
目的了解多囊卵巢综合征(PCOS)患者的血纤溶能力及服用二甲双胍后血纤溶能力的变化. 方法 (1)对照组20例、PCOS患者30例,分别取血检测组织纤溶酶原激活物(t-PA)、纤溶酶原激活抑制物(PAI-1)的活性;(2)PCOS高胰岛素血症者10例,分别给予二甲双胍750～1 500 mg/d治疗,比较治疗前、后t-PA、PAI-1活性. 结果 PCOS组的血胰岛素(INS)、游离睾酮(F-T)、t-PA、PAI-1分别为(24.42±12.30)mU/L、(2.70±1.50)ng/L、(0.17±0.06)KU/L、(0.88±0.05)AU/ml,对照组分别为(10.04±6.12)mU/L、(1.70 ±1.00)ng/L、(0.28±0.04)KU/L、(0.70±0.09)AU/ml.10例PCOS患者经二甲双胍治疗后INS、F-T、t-PA、PAI-1分别为(12.20±7.78)mU/L、(1.70 ±1.00)ng/L、(0.26±0.08)KU/L、(0.70±0.35)AU/ml. 结论 PCOS患者的血纤溶能力低于正常者,而服用二甲双胍后血纤溶能力明显改善.
Objective： To evaluate the plasminogen activator system m women with polycystic ovary syndrome （PCOS） and determine whether metformin would increase the plasminogen activation in PCOS patients. Methods： （1） Serum free-testosterone （F-T）, insulin （INS）, tissue plasminogen activator （t-PA）, plasminogen activator inhibitor type-1 （PAI-1） activity of thirty women with PCOS and twenty controls were measured. （2） F-T, INS, t-PA, PAI-1 were also measured before and after a month oral administration of metformin 750-1 500 mg daily in ten PCOS women with hyperinsulinism. Results： The women with PCOS had higher serum levels of insulin （x±s）：（24.42±12.30）mU/L, higher F-T （2.70±1.50）ng/L, lower t-PA （0. 17±0. 06）KU/L and higher PAI-1 （0. 88±0.05）AU/ml than controls （10. 04± 6.12）mU/L, （1.70±1. 00）ng/L, （0. 28±0.04）KU/L, （0. 70±0.09）AU/ml, respectively. The indices of serum INS, F-T, t-PA and PAId were significantly improved after one month of metformin administration in the PCOS patient with hyperinsulinism. Conclusion： The fibrolysis activity is lower in women with PCOS and could be improved by metformin.
出处
《生殖医学杂志》
CAS
2005年第5期277-279,共3页
Journal of Reproductive Medicine
关键词
多囊卵巢综合征
二甲双胍
血纤溶能力
纤溶酶原激活抑制物
Polycystic ovary syndrome
Metformin
Tissue plasminogen activator
Plasminogenactivator inhibitor type-1
